R1 Therapeutics raises $77.5M to advance AP306 in dialysis-related hyperphosphatemia
TL;DR Summary
R1 Therapeutics secures $77.5 million to push AP306, a hyperphosphatemia treatment, into Phase 2b for dialysis patients, with a potential late- decade market launch.
Topics:business#ap306#biotech#dialysis-medication#hyperphosphatemia-treatment#kidney-disease-biotech#r1-therapeutics
- New renal disease biotech R1 Therapeutics nabs $77.5M for Phase 2b Endpoints News
- R1 zooms out of stealth with $77.5M series A to advance chronic kidney disease treatment Fierce Biotech
- R1 starts up with $78M, aiming for a better kidney drug BioPharma Dive
- Biotechnology Start-Up Partners with Alebund Pharmaceuticals to Develop New Therapy for Hyperphosphatemia in CKD Patients geneonline.com
- Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306 Yahoo Finance
Reading Insights
Total Reads
1
Unique Readers
2
Time Saved
3 min
vs 3 min read
Condensed
95%
524 → 24 words
Want the full story? Read the original article
Read on Endpoints News